Please assess the completion status of the following clinical trial:

Trial Title: SUBLIVAC FIX Birch Phase III Short-term Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age ≥ 18 and ≤65 years~* Moderate-to-severe birch pollen induced allergic rhinitis/rhinoconjunctivitis based on ARIA classification for at least 2 consecutive years~* FEV1 (forced expiratory volume at one second) \> 70% (of predicted value) for patients with a history of asthma, FEV1 \> 70% or PEF (peak expiratory flow) \> 80% (of predicted value) for patients without a history of asthma~* Positive SPT (skin prick test) for birch pollen (mean wheal diameter ≥ 3mm compared to negative control; negative control should be negative; histamine control should be positive (mean wheal diameter ≥ 3mm)) assessed during screening.~* Serum specific anti-birch IgE (immunoglobulin E) concentration \>0.7 U/ml~* Patients should be willing and capable to complete an e-diary daily during the birch pollen season (≥ 60% compliance in completion between Visit 1 and 2).~* A positive Nasal Provocation Test to birch pollen at Visit 2 (Lebel score ≥ 6) or a documented positive test within 1 year before start of treatment~Exclusion Criteria:~* Patients sensitized and symptomatic to pets should not be included if they are regularly exposed to pets~* Specific immunotherapy (SCIT or SLIT) with birch pollen or a cross-reacting allergen within the last 5 years~* SPT positive (mean wheal diameter ≥ 3mm compared to negative control; negative control should be negative; histamine control should be positive (mean wheal diameter ≥ 3mm)) patients to allergen(s) other than birch pollen, in the absence of a negative provocation test for this allergen(s) (within 1 year), who are expected to have clinically relevant symptoms during the birch pollen season~* Completed unsuccessful allergen-specific immunotherapy (SCIT or SLIT) within the last 5 years~* (Ongoing) allergen-specific immunotherapy (SCIT or SLIT) with any allergen(s) during the study period~* Vaccination one week before start of treatment and/or during the up-dosing phase~* Treatment with experimental products within the last 3 months or biologicals (including anti-IgE or TNF (tumor necrosis factor) - α treatment) within the last 6 months or during the study~* Uncontrolled asthma or other active respiratory diseases~* Clinically significant chronic sinusitis, ocular infection or severe inflammation of the oral mucosa~* Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs~* Active malignancies or any malignant disease in the last 5 years~* Acute or chronic disease that in the opinion of the investigator is an additional risk for the patients, including but not limited to the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine disorders, clinically significant renal or hepatic diseases, or haematological disorders~* Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism, glaucoma)~* Use of systemic corticosteroids 4 weeks before the study~* Treatment with systemic or local β-blockers~* Known hypersensitivity to any of the excipients (Disodium phosphate dihydrate, Sodium dihydrogen phosphate dehydrate, aminocaproic acid, Peppermint oil, Caramel Colorant or Glycerol)~* A positive urine pregnancy test, lactation or inadequate contraceptive methods (adequate methods: oral contraceptives, IUD (intrauterine device), condom use and having no sexual relationship with a man)~* Alcohol-, drug or medication abuse~* Lack of co-operation or compliance~* Severe psychiatric, psychological, or neurological disorders~* Any physical or mental condition that precludes administration or allergen-specific immunotherapy, compliance or participation in a clinical trial~* Patients who are employees of the department, 1st grade relatives, or partners of the investigator~* Patients who have planned holidays outside the country for more than 7 continuous days during the defined pollen season (1st of March till 31st of May)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SUBLIVAC FIX Birch 0 AUN/ml (Type: PLACEBO_COMPARATOR): None
- SUBLIVAC FIX Birch 40,000 AUN/ml (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete